5438282026-07-012026-09-305438282026-09-305438282026-03-315438282026-04-012026-09-305438282026-07-012026-09-30in-capmkt:OtherExpenses1Member5438282026-04-012026-09-30in-capmkt:OtherExpenses1Member5438282026-09-30OtherNoncurrentFinancialAssetsDomain15438282026-09-30OtherNoncurrentAssetsDomain15438282026-09-30OtherCurrentFinancialAssetsDomain15438282026-09-30OtherCurrentAssetsDomain15438282026-09-30OtherNoncurrentFinancialLiabilitiesDomain15438282026-09-30OtherNoncurrentFinancialLiabilitiesDomain25438282026-09-30OtherNoncurrentLiabilitiesDomain15438282026-09-30OtherCurrentFinancialLiabilitiesDomain15438282026-09-30OtherCurrentFinancialLiabilitiesDomain25438282026-09-30OtherCurrentLiabilitiesDomain15438282026-09-30OtherCurrentLiabilitiesDomain25438282026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15438282026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15438282026-07-012026-09-30AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares543828SUDARSHANNOTLISTEDINE00TV01023SUDARSHAN PHARMA INDUSTRIES LIMITEDMain BoardEquity2026-04-012027-03-312026-10-292026-10-26INRLakhsQuarterlySecond quarterSingle segmentChemicals and Solvents2026-10-2919:00:002026-10-2922:00:00trueCash Flow IndirectDeclaration of unmodified opinion2026-07-012026-09-30UnauditedConsolidated2169693000193260002189019000726140001921273000-15548200020384000103552000135560001050960002080993000108026000010802600036691000-646800030223000077803000000077803000430007784600080875000-30720000025447100010.310.31000.310.310.01990.01790.01751. The Statement has been reviewed by Members of the Audit Committee and approved by the Board of Directors at their respective meetings held on October 29, 2026. The statutory auditors have issued an unmodified report on these results. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and rules amended from time to time. <br /> 2. The Holding Company is engaged in manufacturing of API, Jobwork manufacturing in Pharmaceuticals items and traders in chemicals and solvents in India. The Group is engaged in the business of speciality chemicals only and therefore, there is only one reportable segment. There is no reportable segment and the segment wise disclosure requirement of lND AS 108 on operating segment is not applicable to it. <br /> 3. The previous periods’ figures have been re-grouped / re-arranged / re-casted wherever necessary to make it comparable with the current period. <br /> 4. The Statutory Auditors have conducted a limited review of the above mentioned quarterly and half year results as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Report of the statutory auditors will be uploaded on the BSE portal along with the results and is also available on the Group's website www.sudarshanpharma.com. <br /> 5. W.e.f. 27th October 2026, the Group successfully completed the migration of its equity shares from the SME Platform of BSE Limited to the Main Board of BSE Limited and listing on the main board of National Stock Exchange of India Limited, in accordance with the applicable provisions of the Securities and Exchange Board of India (SEBI) regulations and the relevant rules, circulars and guidelines. <br /> 6. During the Quaterly and half Year ended 30th September, 2026, the Group decided to discontinue its manufacturing operations at the Palghar unit. The decision was taken after evaluating the unit’s operating performance and its contribution to the Group’s financial results. The closure is expected to help the Group rationalize fixed and operating costs, minimize further losses, and enable management to focus its resources on more sustainable and profitable operations. <br /> 7. Vide letter dated 31st July, 2024 to BSE Limited on the progress of the litigation against Regans International DMCC, the Company had won an award in its favour announced by the Dubai Court in lawsuit against (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal in Dubai, United Arab Emirates. According to the award announced, (i) Regans International DMCC and (i) Nand Biharilal Chhabaria Biharilal Chunilal have been ordered to pay to the Company an amount of UAE Dirham 40,30,934.00 (equivalent to approx. Rs.9,18,82,890/- i.e. Rupees Nine Crores Eighteen Lakhs Eighty Two Thousand Eight Hundred And Ninety only) along with interest at 5% annually on the adjudged amount until the full payment is made. Till 30th September, 2026, the Company had received an amount of Rs.7,48,81,069/- (including interest) out of the total outstanding amount and the balance would be received by the Company in future. <br /> 8. The Board of Directors of the Group accorded it’s consent to raise funds up to Rs.1,500 Crores (Rupees Fifteen Hundred Crores) by issuing Foreign Currency Convertible Bonds (FCCBs) and other securities. At the Board Meeting held on 15th May 2026, the Directors accorded its approval to issue of upto U.S. $ 20,000,000 8.00% senior unsecured foreign currency convertible bonds due 2029, in one or more tranches. At the Board Meeting held on 21st May 2026, the Directors accorded its approval to issue and allot U.S.$10,000,000 aggregate value of FCCBs to the subscribers, with an option with the Group to procure subscribers for up to an additional U.S.$10,000,000 of Bonds on the same terms within 60 days from the Issue Date and approved and confirmed the allotment of 10,000 8% senior unsecured foreign currency convertible bonds due 2029 of face value of USD 1,000 each, convertible into fully paid-up equity shares of face value of Re.1 each of the Group at a price of Rs.30.19/-. The proceeds of the aforesaid allotment were received in tranches on 27th May 2026 and 4th June 2026 comprising of USD 900,000 and USD 100,000 respectively. The above FCCBs are accounted in accordance with Ind AS 32 on Financial Instruments: Presentation and Ind AS 109 - Financial Instruments. At the FCCB Committee Meeting held on 19th August 2026, approved the allotment of 48,11,730 (Forty Eight Lakhs Eleven Thousand Seven Hundred And Thirty) fully paid-up equity shares of face value Rs.1/- each upon conversion of Foreign Currency Convertible Bonds (FCCBs) worth USD 15,00,000. The equity shares were been allotted at an issue price of Rs.30.19 per share, comprising a premium of Rs. 29.19 per share. Following the aforesaid allotment, the total issued equity shares of the Company stand at 25,44,70,600, aggregating to an issued equity share capital of Rs. 25,44,70,600/- <br /> 9. The Warrants Committee of the Group at its Meeting held on 12th June 2026 accorded it’s approval to allot 90,00,000 equity shares of face value of Re.1/- each at an issue price of Rs.16.98 each (including a premium of Rs.15.98 each), consequent upon the conversion of 9,00,000 Warrants issued at an Issue Price of Rs.169.83 each on 18th December 2024, to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters, on preferential basis, upon receipt of balance amount aggregating to Rs.11,46,20,000/- per warrant (being 75% of the issue price per warrant) from the allottees pursuant to the exercise of their rights of conversion into equity shares. Consequently, the issued and paid-up capital of the Company stands increased to Rs.24,96,58,870/- consisting of 24,96,58,870 equity shares of Re. 1/- each <br /> 10. As at September 30, 2026 and June 30, 2026, there are potential dilutive equity share in the nature of FCCB. The potential dilutive equity shares has an anti-dilutive effect. Hence no dilution effect has been considered for the quarter ended September 30, 2026 and June 30, 2026. <br /> 11. On 28th September 2026, the Group completed sale of 2,09,100 equity shares of Rs.10/- each (51.00% of the total paid-up capital of Ishwari) held by the Group in Ishwari Healthcare Private Limited, subsidiary company at a consideration of Rs.1.40 Crores. Consequent to the aforesaid sale, the shareholding of the Group in Ishwari has been reduced from 51.00% to Nil and Ishwari has ceased to be a subsidiary of the Company.) <br /> 12. The Group has incorporated the following subsidiary company during the period ended 30 September 2026: W. e. f. 5t June, 2026, “Sudarshan Industries Inc.” (hereinafter referred to as “Sudarshan USA”) was incorporated as a wholly-owned subsidiary of the Company. The Group has subscribed to 1,00,00,000 shares of USD0.00001 each of Sudarshan USA (approx. Rs.9,600/-) (100.00% of the paid-up share capital). The main object of Sudarshan USA is to carry on the business to buy, sale, manufacture, process, import, export, promote, develop, wholesale and / or retail trade in all kinds and varieties of pharmaceuticals, antibiotics, drugs, medicines, biological, neutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, pharma intermediates, Active Pharmaceutical Ingredients, antibiotics, drugs, medicines, biologicals, neutraceuticals chemicals, chemical products, chemical compounds including speciality chemicals and other allied goods. <br /> 13. The accounts of the following subsidiaries of the Holding company have been considered while preparing consolidated Financial Results / Statements of the Group: <br /> *Sudarshan Pharma Lifescience Private Limited <br /> *Lifescience Chemical Private Limited <br /> *Ratna Lifesciences Private Limited <br /> * Sudarshan Maven Pharma Private Limited <br /> * Ishwari Healthcare Private Limited (upto 28th September 2026) <br /> * Sudarshan Pharma Industries Private Limited, Singapore <br /> * Cibachem General Trading LLC, Dubai (w.e.f 5th August 2025) <br /> * Sudarshan Pharma Poland Limited Liability Company, Poland (w.e.f. 17th December 2025) <br /> * Sudarshan Industries Inc, USA (w.e.f. 5th June 2026) <br /> 2026-04-012026-09-30UnauditedConsolidated39138770003152300039454000001523670003608568000-42504900041068000185623000276170001721270003762321000183079000018307900058672000-9490000491820000133897000000013389700086000133983000139427000-55300000025447100010.540.54000.540.540.01990.01740.0172Other Expenses105096000Other Expenses172127000729805000794570001131100004918900094961000000220000057431400057433600071500006085600017088640002542431000025059870001174100003132300054499000030940410000274188000591066000076195240002544710001700148000195461900069100019553100001463857000000183260001482183000016380000224500014860660002433864000696879000903755000160063400086410004043139000838100001266280000417814800056642140007619524000Other non-current financial assets574314000Other non-current assets60856000Other current financial assets544990000Other current assets274188000Other non-current financial liabilities3327000Lease liabilities14999000Employee benefit obligations2245000Lease liabilities6707000Other financial liabilities1934000Employee benefit obligations220000Other current liabilities8161000185623000-404577000-2734270000-444400000-99200000-2154070000-372670000276170000141000235000002298100001416000000000216420000-700963000-51788400000092250000-5271090000470000000023432200000000-16900000000000000000000000218500000-685237000001146350000000012571150000529500001534480000-268000121273900039300003930001134800011741000Remeasurement (loss)/gain on defined benefit plan Grauity and Leave5700057000Remeasurement (loss)/gain on defined benefit plan Grauity and Leave1150001150001400029000004300086000UnauditedtrueNGST & Associatestrue2027-08-31